Treatment of attention-deficit/hyperactivity disorder
AssigneeAbbott Laboratories
InventorsEarle E. Bain, Walid M. Abi-Saab, Sandeep Dutta, Tushar S. Garimella, Walid M. Awni, Mario D. Saltarelli
Life of this patent
Estimating the term…
Abstract
3-(5,6-Dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane and salts thereof are effective nicotinic receptor agonist compounds that demonstrated pharmacological effect for symptoms associated with attention-deficit/hyperactivity disorder.
Claims8
A method of treating attention-deficit/hyperactivity disorder in a subject in need thereof, comprising administering to a human patient in need of treatment for attention-deficit/hyperactivity disorder an amount of 3-(5,6-dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane or salt thereof that is about 2 mg to about 4 mg.
An article of manufacture comprising:
- (a) a packaging material;
- (b) a neuronal nicotinic acetylcholine receptor agonist;
- and
- (c) a label or package insert contained within the packaging material indicating that 3-(5,6-dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane is administered in an amount of about 2 mg to about 4 mg.
Dependencies are inferred from the claim text.